Abstracts tagged "genetics and tophaceous gout"

Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Nicholas Sumpter¹, Tony Merriman ², Richard Reynolds ³, Abhishek Abhishek ⁴, Mariano Andrés ⁵, Nicola Dalbeth ⁶, Michael Doherty ⁴, Lennart Jacobsson ⁷, Matthijs Janssen ⁸, Tim Jansen ⁹, Leo Joosten ¹⁰, Meliha Kapetanovic ¹¹, Frédéric Lioté ¹², Hirotaka Matsuo ¹³, Geraldine McCarthy ¹⁴, Fernando Perez-Ruiz ¹⁵, Philip Riches ¹⁶, Pascal Richette ¹⁷, Edward Roddy ¹⁸, Blanka Stiburkova ¹⁹, Alex So ²⁰, Lisa Stamp ²¹, Anne-Kathrin Tausche ²², Rosa Torres-Jimenez ²³ and Till Uhlig ²⁴, ¹University of Otago, Birmingham, ²University of Otago, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Nottingham, Nottingham, United Kingdom, ⁵Hospital General Universitario de Alicante, Alicante, Spain, ⁶University of Auckland, Auckland, New Zealand, ⁷Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁸Rijnstate Hospital, Arnhem, Netherlands, ⁹Viecuri MC, Venlo, Netherlands, ¹⁰Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands, ¹¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹²Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ¹³National Defense Medical College, Tokorozawa, Japan, ¹⁴University College Dublin, Dublin, Ireland, ¹⁵Hospital de Cruces, Vizcaya, Spain, ¹⁶The University of Edinburgh, Edinburgh, United Kingdom, ¹⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ¹⁸Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ¹⁹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²⁰Universite de Lausanne, Lausanne, Switzerland, ²¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²²Universitatsklinikum Dresden, Dresden, Germany, ²³Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain, ²⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].